Supernus Pharmaceuticals Inc (SUPN)

Debt-to-equity ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	0	0	400,382	379,252	374,788	370,383	366,038	361,751	357,521	353,349	349,232
Total stockholders’ equity	US$ in thousands	1,035,730	1,007,150	957,454	929,166	921,516	912,191	919,908	912,150	886,204	852,798	841,434	828,446	815,851	810,468	785,579	754,444	744,858	708,879	665,974	613,383
Debt-to-equity ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.48	0.46	0.46	0.47	0.49	0.49	0.50	0.53	0.57

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $1,035,730K
= 0.00

The debt-to-equity ratio of Supernus Pharmaceuticals Inc has shown a decreasing trend over the past few years, indicating a decreasing reliance on debt financing relative to equity.

As of December 31, 2024, the debt-to-equity ratio is at 0.00, signaling that the company has no debt on its balance sheet in relation to its equity. This could imply a strong financial position, as lower debt levels generally reduce the financial risk for the company.

It is important to note that the sudden drop to 0.00 starting from June 30, 2022, raises questions about the accuracy of the data. An abrupt change to zero debt could be due to various reasons, such as debt repayment, refinancing, or a reporting error. Further investigation would be needed to confirm the reliability of this sudden change in the debt-to-equity ratio.